Bevacizumab-Maly: uses, dosing, side effects & brands
Bevacizumab-Maly is a medicine sold in the U.S. under one brand, for non-small-cell lung carcinoma, uterine cervical neoplasms and fallopian tube neoplasms. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Treats
- Non-Small-Cell Lung Carcinoma, Uterine Cervical Neoplasms and Fallopian Tube Neoplasms
- Available as
- Injectable
- Sold as
- Alymsys
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
How bevacizumab-maly is dosed
From the FDA label for Alymsys (application BLA761231). Other bevacizumab-maly products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Withhold for at least 28 days prior to elective surgery. Do not administer Alymsys for 28 days following major surgery and until adequate wound healing. (2.1) Metastatic colorectal cancer (2.2) 5 mg/kg every 2 weeks with bolus-IFL 10 mg/kg every 2 weeks with FOLFOX4 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy after progression on a first-line bevacizumab product-containing regimen First-line non−squamous non−small cell lung cancer (2.3) 15 mg/kg every 3 weeks with carboplatin and paclitaxel Recurrent glioblastoma (2.4) 10 mg/kg every 2 weeks Metastatic renal cell carcinoma (2.5) 10 mg/kg every 2 weeks with interferon alfa Persistent, recurrent, or metastatic cervical cancer (2.6) 15 mg/kg every 3 weeks with paclitaxel and cisplatin, or paclitaxel and topotecan Platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer (2.7) 10 mg/kg every 2 weeks with paclitaxel, pegylated liposomal doxorubicin, or topotecan given every week 15 mg/kg every 3 weeks with topotecan given every 3 weeks Administer as an intravenous infusion (2.9) 2.1 Important Administration Information Withhold for at least 28 days prior to elective surgery. Do not administer Alymsys until at least 28 days following major surgery and until adequate wound healing. 2.2 Metastatic Colorectal…
Bevacizumab-Maly side effects
The following clinically significant adverse reactions are described elsewhere in the labeling: Gastrointestinal Perforations and Fistulae [see Warnings and Precautions (5.1)] . Surgery and Wound Healing Complications [see Warnings and Precautions (5.2)] . Hemorrhage [see Warnings and Precautions (5.3)] . Arterial Thromboembolic Events [see Warnings and Precautions (5.4)] . Venous Thromboembolic Events [see Warnings and Precautions (5.5)] . Hypertension [see Warnings and Precautions (5.6)] . Posterior Reversible Encephalopathy Syndrome [see Warnings and Precautions (5.7)] . Renal Injury and Proteinuria [see Warnings and Precautions (5.8)] . Infusion-Related Reactions [see Warnings and Precautions (5.9)] . Ovarian Failure [see Warnings and Precautions (5.11)] . Congestive Heart Failure [see Warnings and Precautions (5.12)] . Most common adverse reactions incidence (incidence > 10%) are epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, hemorrhage, lacrimation disorder, back pain and exfoliative dermatitis. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Valorum Biologics, LLC at 1-844-576-2709 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to…
Who shouldn’t take bevacizumab-maly
None. None (4)
Bevacizumab-Maly drug interactions
Effects of Alymsys on Other Drugs No clinically meaningful effect on the pharmacokinetics of irinotecan or its active metabolite SN38, interferon alfa, carboplatin or paclitaxel was observed when bevacizumab was administered in combination with these drugs; however, 3 of the 8 patients receiving bevacizumab with paclitaxel and carboplatin had lower paclitaxel exposure after four cycles of treatment (at Day 63) than those at Day 0, while patients receiving paclitaxel and carboplatin alone had a greater paclitaxel exposure at Day 63 than at Day 0.
Every bevacizumab-maly product we track (1)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
Only one: Alymsys.
What people report to the FDA about bevacizumab-maly
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 3 reports naming bevacizumab-maly, and the FDA flagged 100% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- deep vein thrombosis1 reports
- gastrointestinal haemorrhage1 reports
- pneumonia1 reports
- seizure1 reports
- shock haemorrhagic1 reports
- vomiting1 reports
Read these as a signal, not a rate. A report does not mean bevacizumab-maly caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.
Source: openFDA drug/event (FAERS), retrieved July 25, 2026.
Related calculators
Frequently asked questions
What is bevacizumab-maly?
Alymsys (Bevacizumab-Maly) is a medication used to treat Non-Small-Cell Lung Carcinoma, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Glioblastoma.
Can you take bevacizumab-maly with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run bevacizumab-maly against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What forms does bevacizumab-maly come in?
Across the brands we track, bevacizumab-maly is currently marketed as injectable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic bevacizumab-maly?
We do not currently list a generic-labelled bevacizumab-maly product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Bevacizumab-Maly: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/bevacizumab-maly
- MLA
- “Bevacizumab-Maly: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/bevacizumab-maly.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for bevacizumab-maly on DailyMed (NIH) ↗.